| 90 0 (0%) | 01-02 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.
Wed, 08 Jul 2026
Merus (MRUS) Investor Update Summary - quartr.com
Tue, 30 Dec 2025
Genmab completes acquisition of Merus and delists shares from Nasdaq - Investing.com
Tue, 30 Dec 2025
Merus Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Mon, 17 Nov 2025
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PR Newswire
Mon, 06 Oct 2025
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|